Studies in animal models of arthritis and lupus have shown that treatment with anti-HMGB1 antibodies can strikingly attenuate disease by blocking the pro-inflammatory function of HMGB1 [52–54]. Here, HMGB1 is linked to systemic lupus erythematosus.